^
Association details:
| Biomarker: | TP53 deletion |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial
Published date:
11/23/2021
Excerpt:
Among the 24 TP53 evaluable pts, eight pts (33%) had TP53 aberrations (mutated and/or TP53 deletion by FISH). Forty-eight pts received IRV. Best response to IRV was 96% and CR of 92%. After part 2, the best ORR remained unaltered, 96% (92% CR and 4% PR). The median number of cycles of triplet IRV to reach best response was 8 cycles (range 2-12). Fifteen pts (30%) did not receive part 2 chemotherapy, two pts (4%) received 1 cycle, 16 pts (32%) 2 cycles and 13 pts (26%) got 4 cycles of chemotherapy. Chemotherapy-free induction with IRV induced durable and deep responses in young MCL pts in the frontline setting.
DOI:
https://doi.org/10.1182/blood-2021-153390
Trial ID:
Source:
Title:
Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-2 Clinical Trial
Published date:
11/04/2021
Excerpt:
We enrolled 50 previously untreated pts in this single institution, single arm, phase II clinical trial – NCT03710772....Among the 24 TP53 evaluable pts, eight pts (33%) had TP53 aberrations (mutated and/or TP53 deletion by FISH). Forty-eight pts received IRV. Best response to IRV was 96% and CR of 92%. After part 2, the best ORR remained unaltered, 96% (92% CR and 4% PR).
DOI:
10.1182/blood-2021-153390
Trial ID:
